CA3036770A1 - Stable pharmaceutical foam - Google Patents
Stable pharmaceutical foam Download PDFInfo
- Publication number
- CA3036770A1 CA3036770A1 CA3036770A CA3036770A CA3036770A1 CA 3036770 A1 CA3036770 A1 CA 3036770A1 CA 3036770 A CA3036770 A CA 3036770A CA 3036770 A CA3036770 A CA 3036770A CA 3036770 A1 CA3036770 A1 CA 3036770A1
- Authority
- CA
- Canada
- Prior art keywords
- full
- peptone
- protein
- foam
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008255 pharmaceutical foam Substances 0.000 title claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 181
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 181
- 239000001888 Peptone Substances 0.000 claims abstract description 161
- 108010080698 Peptones Proteins 0.000 claims abstract description 161
- 235000019319 peptone Nutrition 0.000 claims abstract description 161
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims abstract description 65
- 230000007071 enzymatic hydrolysis Effects 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000000413 hydrolysate Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 235000018102 proteins Nutrition 0.000 claims description 179
- 239000006260 foam Substances 0.000 claims description 178
- 239000000243 solution Substances 0.000 claims description 76
- 108010010803 Gelatin Proteins 0.000 claims description 68
- 239000008273 gelatin Substances 0.000 claims description 68
- 229920000159 gelatin Polymers 0.000 claims description 68
- 235000019322 gelatine Nutrition 0.000 claims description 68
- 235000011852 gelatine desserts Nutrition 0.000 claims description 68
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 45
- 239000003531 protein hydrolysate Substances 0.000 claims description 45
- 238000005187 foaming Methods 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 108090000190 Thrombin Proteins 0.000 claims description 25
- 229960004072 thrombin Drugs 0.000 claims description 25
- 239000005018 casein Substances 0.000 claims description 24
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 24
- 235000021240 caseins Nutrition 0.000 claims description 24
- 108010049003 Fibrinogen Proteins 0.000 claims description 22
- 102000008946 Fibrinogen Human genes 0.000 claims description 22
- 229940012952 fibrinogen Drugs 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 21
- 230000007062 hydrolysis Effects 0.000 claims description 18
- 238000006460 hydrolysis reaction Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229910001868 water Inorganic materials 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 238000007789 sealing Methods 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 108091005502 Aspartic proteases Proteins 0.000 claims description 4
- 102000035101 Aspartic proteases Human genes 0.000 claims description 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 4
- 108091005503 Glutamic proteases Proteins 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 108091005501 Threonine proteases Proteins 0.000 claims description 4
- 102000035100 Threonine proteases Human genes 0.000 claims description 4
- 230000023597 hemostasis Effects 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 description 30
- 238000007906 compression Methods 0.000 description 29
- 230000006835 compression Effects 0.000 description 29
- 108010076119 Caseins Proteins 0.000 description 22
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 22
- 229940066779 peptones Drugs 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000006193 liquid solution Substances 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- 238000005903 acid hydrolysis reaction Methods 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 208000031737 Tissue Adhesions Diseases 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 108010009004 proteose-peptone Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007065 protein hydrolysis Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000008258 liquid foam Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0042—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394371P | 2016-09-14 | 2016-09-14 | |
| IL247810 | 2016-09-14 | ||
| US62/394,371 | 2016-09-14 | ||
| IL247810A IL247810A0 (en) | 2016-09-14 | 2016-09-14 | Stable pharmaceutical foam |
| PCT/IL2017/000007 WO2018051325A1 (en) | 2016-09-14 | 2017-09-11 | Stable pharmaceutical foam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3036770A1 true CA3036770A1 (en) | 2018-03-22 |
Family
ID=60022140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036770A Abandoned CA3036770A1 (en) | 2016-09-14 | 2017-09-11 | Stable pharmaceutical foam |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3512502A1 (ko) |
| JP (1) | JP7114597B2 (ko) |
| KR (1) | KR102656742B1 (ko) |
| CN (1) | CN109789091A (ko) |
| AU (1) | AU2017328480A1 (ko) |
| CA (1) | CA3036770A1 (ko) |
| IL (1) | IL265252B2 (ko) |
| MA (1) | MA46239A (ko) |
| WO (1) | WO2018051325A1 (ko) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2492458A (en) | 1944-12-08 | 1949-12-27 | Jr Edgar A Bering | Fibrin foam |
| CH264752A (de) * | 1947-06-03 | 1949-10-31 | Hoffmann La Roche | Verfahren zur Herstellung von Trägern für Arzneimittel. |
| JPS5814813B2 (ja) * | 1976-11-09 | 1983-03-22 | 味の素株式会社 | 起泡剤及びその製造法 |
| US6454787B1 (en) | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
| JP5133482B2 (ja) | 1999-07-21 | 2013-01-30 | イムデ ビオマテリオー | 外科的及び／又は治療的使用のための接着性タンパク質フォーム、並びにその生産のための方法及びキット |
| JP2003523409A (ja) | 2000-02-25 | 2003-08-05 | デイビッド シエラ | 泡形成創傷被覆剤 |
| JP4113781B2 (ja) | 2001-03-26 | 2008-07-09 | バイエル アクチェンゲゼルシャフト | 顕著な「ずり流動化特性」を示す溶融重合ポリカーボネート |
| US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
| US6749842B2 (en) * | 2002-01-24 | 2004-06-15 | Midwest Grain Products | Liquid foam builder containing hydrolyzed grain protein |
| US8202549B2 (en) | 2007-08-14 | 2012-06-19 | The Regents Of The University Of California | Mesocellular oxide foams as hemostatic compositions and methods of use |
| CA2710798A1 (en) * | 2007-12-28 | 2009-07-09 | Kuros Biosurgery Ag | Pdgf fusion proteins incorporated into fibrin foams |
| CN102014973A (zh) * | 2008-02-29 | 2011-04-13 | 弗罗桑医疗设备公司 | 用于促进止血和/或伤口愈合的装置 |
| KR101541702B1 (ko) * | 2008-03-03 | 2015-08-04 | 옴릭스 바이오파머슈티컬스 리미티드 | 활성 성분을 포함하는 젤라틴 스펀지, 이의 제조 방법 및 용도 |
| US8753670B2 (en) | 2008-03-26 | 2014-06-17 | Baxter International Inc. | Fibrin foam and process |
| US8512740B2 (en) | 2008-03-26 | 2013-08-20 | Baxter International Inc. | Fibrin foam and process for making |
| US20110036133A1 (en) * | 2008-04-18 | 2011-02-17 | N. V. Organon | Purification of protein hydrolysate and the result and products |
| US20100021527A1 (en) | 2008-07-25 | 2010-01-28 | Chunlin Yang | Collagen-related peptides and uses thereof and hemostatic foam substrates |
| US8778883B2 (en) | 2009-11-13 | 2014-07-15 | Industrial Technology Research Institute | Foamy biomaterial for biological tissue repair |
| RU2013155713A (ru) * | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
| US8680240B1 (en) | 2012-11-01 | 2014-03-25 | George David Falus | Tissue sealant for use in non-compressible hemorrhage |
| US10307509B2 (en) | 2012-12-07 | 2019-06-04 | Baxter International Inc. | Hemostatic foam |
| CN105543315A (zh) * | 2015-12-16 | 2016-05-04 | 陕西科技大学 | 胶原蛋白类发泡剂、其复配改性发泡剂以及二者的制备方法 |
-
2017
- 2017-09-11 KR KR1020197010499A patent/KR102656742B1/ko active IP Right Grant
- 2017-09-11 CN CN201780056569.1A patent/CN109789091A/zh active Pending
- 2017-09-11 JP JP2019536003A patent/JP7114597B2/ja active Active
- 2017-09-11 WO PCT/IL2017/000007 patent/WO2018051325A1/en unknown
- 2017-09-11 IL IL265252A patent/IL265252B2/en unknown
- 2017-09-11 AU AU2017328480A patent/AU2017328480A1/en not_active Abandoned
- 2017-09-11 MA MA046239A patent/MA46239A/fr unknown
- 2017-09-11 CA CA3036770A patent/CA3036770A1/en not_active Abandoned
- 2017-09-11 EP EP17780529.8A patent/EP3512502A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR102656742B1 (ko) | 2024-04-15 |
| JP2019526646A (ja) | 2019-09-19 |
| MA46239A (fr) | 2019-07-24 |
| CN109789091A (zh) | 2019-05-21 |
| KR20190054110A (ko) | 2019-05-21 |
| IL265252B1 (en) | 2023-07-01 |
| IL265252B2 (en) | 2023-11-01 |
| IL265252A (en) | 2019-05-30 |
| JP7114597B2 (ja) | 2022-08-08 |
| AU2017328480A1 (en) | 2019-03-14 |
| WO2018051325A1 (en) | 2018-03-22 |
| EP3512502A1 (en) | 2019-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109789245B (zh) | 基于血浆的膜及其制造和使用方法 | |
| Burke et al. | Thermal gelation and tissue adhesion of biomimetic hydrogels | |
| AU2013353931B2 (en) | Hemostatic foam | |
| US9694101B2 (en) | Flowable collagen-based hemostat and methods of use | |
| US20050037960A1 (en) | Methods and compositions for sealing tissue leaks | |
| CN111465417B (zh) | 止血用组合物以及包含上述止血用组合物的容器 | |
| CN110801528A (zh) | 一种硬脊膜封合水凝胶及其制备方法与应用 | |
| EP3074055B1 (en) | Dry pad comprising thrombin and pectin | |
| US11938165B2 (en) | Stable pharmaceutical foam | |
| CA3036770A1 (en) | Stable pharmaceutical foam | |
| JP5889188B2 (ja) | 組織接着用シート製剤 | |
| JP2017202033A (ja) | 多糖止血剤 | |
| CA2983798A1 (en) | Haemostatic compositions of fibrongen-binding peptides | |
| WO2013021066A1 (en) | Composition in the form of a film comprising fibrinogen and a fibrinogen activator and the applications thereof | |
| CN101297977A (zh) | 一种生物粘合剂及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220311 |
|
| FZDE | Discontinued |
Effective date: 20220311 |